Trials / Not Yet Recruiting
Not Yet RecruitingNCT05797662
A Study of Propranolol to Treat Kaposi Sarcoma
A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- AIDS Malignancy Consortium · Network
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.
Detailed description
Eligible study participants will receive propanolol twice daily for an initial 12-week period. At the conclusion of 12-weeks, response will be assessed. Participants who achieve a complete or partial response will continue propanolol for an additional 6 weeks or 12 weeks, respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propranolol | Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks |
Timeline
- Start date
- 2026-09-01
- Primary completion
- 2029-04-01
- Completion
- 2029-04-01
- First posted
- 2023-04-04
- Last updated
- 2026-01-23
Locations
9 sites across 8 countries: Argentina, Brazil, Kenya, Malawi, Mexico, South Africa, Uganda, Zimbabwe
Source: ClinicalTrials.gov record NCT05797662. Inclusion in this directory is not an endorsement.